Skip to content
Wenlo
Sign in
← Markets

Bolt Biotherapeutics, Inc.

Sheila Gujrathi (Chief Strategy Officer) reports BOLT insider transactions

4BOLTFiled Oct 27, 2026, 1:21 PM ET· Period Oct 23, 2026

About this filing

Bolt Biotherapeutics, Inc. (BOLT) filed Form 4 (insider transaction) with the SEC on Oct 27, 2026. Form 4 reports a company insider’s trades in the company’s shares.

View original filing on SEC.gov (opens SEC EDGAR)

Key facts

Insider
Sheila Gujrathi · Chief Strategy Officer, Director
DateTransactionSharesPriceValueHeld afterOwnership
Oct 23, 2026A · grantFootnotes F1, F2+72,766$0.00$0.0072,766Direct
Oct 23, 2026A · grantFootnotes F1, F2, F3+13,055$0.00$0.0013,055Indirect (By SilverArc Private Fund I, L.P.)
Oct 23, 2026J · otherSeries D Preferred StockFootnotes F4, F1, F2+2,763.833——2,763.833Direct
Oct 23, 2026J · otherSeries D Preferred StockFootnotes F4, F1, F2, F3+495.874——495.874Indirect (By SilverArc Private Fund I, L.P.)
Footnotes
  1. F1 Received in exchange for shares of common stock of Prana Therapies, Inc. ("Prana") pursuant to the Agreement and Plan of Merger dated October 23, 2026 (the "Merger Agreement") by and among the Issuer, Prana, Prince Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("Merger Sub I"), Prince Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Merger Sub II"). Each outstanding share of Prana common stock was converted into the right to receive 1.6413 shares of the Issuer's common stock or common-stock equivalents, consisting of Issuer's common stock and Series D Convertible Preferred Stock ("Series D Preferred") convertible at a rate of 1,000 shares of Issuer's common stock per share of Series D Preferred. No cash purchase price was paid for the Series D Preferred received as merger consideration.
  2. F2 Upon closing of the merger on October 23, 2026, Prana shares held directly by the Reporting Person converted into 72,766 shares of Issuer's common stock and 2,763.833 shares of Series D Preferred. Prana shares held by SilverArc Private Fund I, L.P. converted into 13,055 shares of Issuer's common stock and 495.874 shares of Series D Preferred. The 495.874 shares of Series D Preferred constitute merger consideration
  3. F3 The Reporting Person is Co-Portfolio Manager and has membership interest in SilverArc Private Capital I, LLC (Ultimate General Partner), SilverArc Private Capital I, LP (General Partner), and SilverArc Private Capital Management I, LP (Management Company) for SilverArc Private Fund I, L.P. The Reporting Person may not be deemed to have voting or investment power over the shares held of record by SilverArc Private Fund I, LP. The Reporting Person disclaims beneficial ownership of the Non-Derivative and Derivative securities held of record by SilverArc Private Fund I, L.P., except to the extent of any pecuniary interest therein.
  4. F4 Each share of Series D Preferred is convertible into 1,000 shares of the Issuer's common stock, subject to the conditions set forth in the Certificate of Designation, including receipt of the requisite stockholder approval. The Series D Preferred has no expiration date.

More BOLT filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.